About this Research Topic
The staging of cancer is one of the most reproducible prognostic factors with the TNM classification based on tumor size (T), nodal (N) and metastatic (M) involvement. However, this does not take the tumor molecular and immune characteristics into account. There has been an increasing number of studies on biological markers that are not routinely measured in clinical practice. Often, these factors are not reproducible and their prognostic independent value is not proven, with adjustment for well-known prognostic factors. Therefore, it is vital to identify further prognostic biomarkers that can be detected at the early stage of the disease and can serve as potential treatment targets.
In this Research Topic we welcome studies that focus on, but are not limited to:
- Prognostic value of tumor metabolic activity in NSCLC
- Prognostic gene signatures in NSCLC
- Long non-coding RNAs as prognostic biomarkers in NSCLC
- Immune-Related Prognostic Biomarkers in NSCLC
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: prognosis, NSCLC, lung cancer, gene signature, lncRNA, immune
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.